Emory University School of Medicine, US, has commenced subject enrolment for BioCardia’s Phase III CardiAMP HF II trial.

With trial costs rising over the past decade and concerns they’ll keep climbing, companies are seeking ways to manage ...

Amgen's global Phase III DeLLphi-304 trial of Imdelltra has met its primary endpoint at a planned interim analysis for ...

Seismic Therapeutic has dosed the first healthy participant cohort in the randomised Phase I trial of bifunctional antibody S ...

J&J has reported data from the Phase III ICONIC-LEAD trial’s subgroup analysis evaluating icotrokinra in treating plaque ...

MaaT Pharma has reported positive results from an interim safety analysis of its Phase IIb trial of MaaT033 in subjects ...

Three companies recently announced progression in their clinical research for next-generation Covid-19 vaccines: INOVIO, ...

AI tools are faster at drafting clinical trial documents, but human writers remain indispensable for logical reasoning.

Oculis has concluded subject enrolment for the Phase III clinical trials of OCS-01 eye drops for diabetic macular oedema.

After dropping the FNAIT therapy, Rallybio will prioritise another candidate that is being investigated in complement-driven ...

LifeMine Therapeutics has dosed the first subject in the Phase I trial of calcineurin inhibitor (CNi), LIFE-001.

Apnimed has dosed the first subject in the Phase IIA RESTEADY trial of SASS-001, an oral drug combo for sleep apnoea with a ...